11 studies found for:    "Acral Lentiginous Melanoma"
Show Display Options
Rank Status Study
1 Recruiting Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 E/K Mutation-Positive Acral Lentiginous Melanoma
Condition: Cancer
Interventions: Drug: Dabrafenib;   Drug: Trametinib
2 Active, not recruiting SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Conditions: Mucosal Lentiginous Melanoma;   Acral Lentiginous Malignant Melanoma
Intervention: Drug: Sunitinib
3 Active, not recruiting Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Conditions: Acral Lentiginous Malignant Melanoma;   Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis
4 Active, not recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Solar Radiation-related Skin Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis
5 Completed AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Intraocular Melanoma;   Iris Melanoma;   Lentigo Maligna Malignant Melanoma;   Recurrent Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Interventions: Drug: cediranib maleate;   Other: laboratory biomarker analysis;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
6 Unknown  A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread
Conditions: Mucosal Lentiginous Melanoma;   Acral Lentiginous Malignant Melanoma
Intervention: Drug: nilotinib
7 Active, not recruiting Dinaciclib in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Mucosal Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Intervention: Drug: dinaciclib
8 Terminated Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
Condition: Melanoma
Interventions: Drug: Dasatinib;   Procedure: Surgical Resection
9 Recruiting Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Condition: Melanoma (Skin)
Interventions: Drug: dasatinib;   Other: laboratory biomarker analysis
10 Recruiting Study of Families With Melanoma
Condition: Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: examination;   Procedure: mutation carrier screening;   Procedure: study of high risk factors
11 Completed Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: adenovirus RSV-TK;   Drug: ganciclovir

Indicates status has not been verified in more than two years